Back to results
US 12,605,363 B2Granted
Oxymetazoline compositions
AssigneeRVL Pharmaceuticals, Inc.
InventorsTina deVries, David Jacobs
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
Claims20
An aqueous ophthalmic, sterile, preservative-free formulation for treating ptosis consisting of:
- a) about 0.1 wt % oxymetazoline hydrochloride;
- b) about 0.64 wt % sodium chloride;
- c) about 0.075 wt % potassium chloride;
- d) about 0.048 wt % calcium chloride;
- e) about 0.03 wt % magnesium chloride;
- f) about 0.05 wt % to about 1.0 wt % one or more suitable buffers;
- g) about 0.5 wt % hypromellose;
- h) hydrochloric acid;
- and
- i) water;
- wherein the formulation has a pH range from about 5.8 to about 6.8,
- wherein the formulation maintains the pH range from about 5.8 to about 6.8 for a period of 24 months, and
- wherein the formulation delivers about 0.035 mg of oxymetazoline hydrochloride per drop.
10 more elements
An aqueous ophthalmic, sterile, preservative-free stable formulation for treating ptosis consisting of:
- a) about 0.1 wt % oxymetazoline hydrochloride;
- b) about 0.64 wt % sodium chloride;
- c) about 0.075 wt % potassium chloride;
- d) about 0.048 wt % calcium chloride;
- e) about 0.03 wt % magnesium chloride;
- f) about 0.39 wt % sodium acetate;
- g) about 0.17 wt % sodium citrate;
- h) about 0.5 wt % of a viscosity modifier;
- i) hydrochloric acid;
- and
- j) water;
- wherein the formulation has a viscosity from about 15 cPs to about 35 cPs,
- wherein the formulation maintains the viscosity from about 15 cPs to about 35 cPs for a period of 24 months, and
- wherein the formulation delivers about 0.035 mg of oxymetazoline hydrochloride per drop.
11 more elements
Dependencies are inferred from the claim text.